China Biotech Services Holdings Limited provided group earnings guidance for the first quarter of 2020. The Group is expected to record a net loss of not less than HKD 24,000,000 for the 2020 first quarter Period as compared to the net loss of approximately HKD 14,958,000 recorded for the corresponding period in 2019. The increase in net loss for the 2020 first quarter Period was mainly attributable to decrease in revenue from medical laboratory testing and health check services segment due to the outbreak of novel coronavirus (COVID -19); a n d increase in administrative expenses of approximately HKD 8,878,000 due to increase in amortisation of intangible assets and research and development costs from tumor immune cell therapy services segment.